Pembrolizumab Nets 2 More Approvals
from OncoPharm Hosted by John Bossaer
Discussing recent FDA-approvals of pembrolizumab for metastatic or unresectable, recurrent Head & Neck Cancer (1st line) and Small Cell Lung Cancer (3rd line)
Embed this episode
No transcript yet.
Frequently asked questions
How long is this episode of OncoPharm?
This episode is 15 minutes long.
When was this OncoPharm episode published?
This episode was published on June 20, 2019.
Can I download this OncoPharm episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.